August 26, 2021 10:40 AM EDTUpdated 11:02 AM

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug

Paul Schloesser

Associate Editor

John Carroll

Editor & Founder

Amneal Pharmaceuticals announced positive results yesterday from a pivotal Phase III clinical trial that evaluated IPX-203 in patients with Parkinson’s disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug

Paul Schloesser

Associate Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Am­neal touts re­sults from Phase III tri­al in Parkin­son's; No­vaRock part­ners on can­cer drug

Associate Editor

Editor & Founder

Sign up to read this article for free.

Amneal touts results from Phase III trial in Parkinson's; NovaRock partners on cancer drug